用在昆虫细胞中表达的犬吉氏巴贝斯虫重组表面抗原P50进行免疫接种可诱导犬体内寄生虫生长抑制。
Immunization with recombinant surface antigen P50 of Babesia gibsoni expressed in insect cells induced parasite growth inhibition in dogs.
作者信息
Fukumoto Shinya, Tamaki Yoh, Shirafuji Hiroaki, Harakawa Shinji, Suzuki Hiroshi, Xuan Xuenan
机构信息
National Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine, Obihiro, Hokkaido, Japan.
出版信息
Clin Diagn Lab Immunol. 2005 Apr;12(4):557-9. doi: 10.1128/CDLI.12.4.557-559.2005.
Abstract
This is a report of a vaccine trial directed against Babesia gibsoni infection in dogs with the use of the recombinant antigen P50. Dogs immunized with P50 showed partial protection manifested as a significantly low level of parasitemia. The results indicated that P50 is a primary vaccine candidate molecule against canine B. gibsoni infection.
摘要
这是一份关于使用重组抗原P50针对犬吉氏巴贝斯虫感染进行疫苗试验的报告。用P50免疫的犬表现出部分保护作用，表现为明显较低水平的寄生虫血症。结果表明，P50是针对犬吉氏巴贝斯虫感染的主要候选疫苗分子。
相似文献
1
Immunization with recombinant surface antigen P50 of Babesia gibsoni expressed in insect cells induced parasite growth inhibition in dogs.
Clin Diagn Lab Immunol. 2005 Apr;12(4):557-9. doi: 10.1128/CDLI.12.4.557-559.2005.
2
Inhibitory effect of antiserum to surface antigen P50 of Babesia gibsoni on growth of parasites in severe combined immunodeficiency mice given canine red blood cells.
Infect Immun. 2004 Mar;72(3):1795-8. doi: 10.1128/IAI.72.3.1795-1798.2004.
3
Serodiagnosis of canine Babesia gibsoni infection by enzyme-linked immunosorbent assay with recombinant P50 expressed in Escherichia coli.
J Parasitol. 2004 Apr;90(2):387-91. doi: 10.1645/GE-147R.
4
Identification and expression of a 50-kilodalton surface antigen of Babesia gibsoni and evaluation of its diagnostic potential in an enzyme-linked immunosorbent assay.
J Clin Microbiol. 2001 Jul;39(7):2603-9. doi: 10.1128/JCM.39.7.2603-2609.2001.
5
Clinical usefulness of antibodies against Babesia gibsoni detected by ELISA with recombinant P50.
J Vet Med Sci. 2006 Dec;68(12):1371-3. doi: 10.1292/jvms.68.1371.
6
Protective efficacy of Babesia gibsoni culture-derived exoantigens against the challenge infection in dogs.
Parasitol Res. 2014 May;113(5):1681-6. doi: 10.1007/s00436-014-3812-1. Epub 2014 Feb 18.
7
Prime-boost immunization with DNA followed by a recombinant vaccinia virus expressing P50 induced protective immunity against Babesia gibsoni infection in dogs.
Vaccine. 2007 Jan 26;25(7):1334-41. doi: 10.1016/j.vaccine.2006.09.083. Epub 2006 Oct 10.
8
High-level expression of truncated surface antigen P50 of Babesia gibsoni in insect cells by baculovirus and evaluation of its immunogenicity and antigenicity.
Clin Diagn Lab Immunol. 2003 Jul;10(4):596-601. doi: 10.1128/cdli.10.4.596-601.2003.
9
Vaccination against canine babesiosis.
Trends Parasitol. 2005 Apr;21(4):179-84. doi: 10.1016/j.pt.2005.02.006.
10
Characterization of the Babesia gibsoni 12-kDa protein as a potential antigen for the serodiagnosis.
Parasitol Int. 2009 Mar;58(1):55-60. doi: 10.1016/j.parint.2008.10.003. Epub 2008 Oct 28.
引用本文的文献
1
The Etiology, Incidence, Pathogenesis, Diagnostics, and Treatment of Canine Babesiosis Caused by Infection.
Animals (Basel). 2022 Mar 16;12(6):739. doi: 10.3390/ani12060739.
2
New Molecules in Babesia gibsoni and their application for diagnosis, vaccine development, and drug discovery.
Korean J Parasitol. 2014 Aug;52(4):345-53. doi: 10.3347/kjp.2014.52.4.345. Epub 2014 Aug 29.
3
Protective efficacy of Babesia gibsoni culture-derived exoantigens against the challenge infection in dogs.
Parasitol Res. 2014 May;113(5):1681-6. doi: 10.1007/s00436-014-3812-1. Epub 2014 Feb 18.
4
Canine babesiosis: from molecular taxonomy to control.
Parasit Vectors. 2009 Mar 26;2 Suppl 1(Suppl 1):S4. doi: 10.1186/1756-3305-2-S1-S4.
本文引用的文献
1
Serodiagnosis of canine Babesia gibsoni infection by enzyme-linked immunosorbent assay with recombinant P50 expressed in Escherichia coli.
J Parasitol. 2004 Apr;90(2):387-91. doi: 10.1645/GE-147R.
2
Inhibitory effect of antiserum to surface antigen P50 of Babesia gibsoni on growth of parasites in severe combined immunodeficiency mice given canine red blood cells.
Infect Immun. 2004 Mar;72(3):1795-8. doi: 10.1128/IAI.72.3.1795-1798.2004.
3
High-level expression of truncated surface antigen P50 of Babesia gibsoni in insect cells by baculovirus and evaluation of its immunogenicity and antigenicity.
Clin Diagn Lab Immunol. 2003 Jul;10(4):596-601. doi: 10.1128/cdli.10.4.596-601.2003.
4
Advances and prospects for subunit vaccines against protozoa of veterinary importance.
Vet Parasitol. 2001 Nov 22;101(3-4):291-310. doi: 10.1016/s0304-4017(01)00557-x.
5
Identification and expression of a 50-kilodalton surface antigen of Babesia gibsoni and evaluation of its diagnostic potential in an enzyme-linked immunosorbent assay.
J Clin Microbiol. 2001 Jul;39(7):2603-9. doi: 10.1128/JCM.39.7.2603-2609.2001.
6
Enhanced immunogenicity of CD4(+) t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis.
Infect Immun. 2001 Feb;69(2):681-6. doi: 10.1128/IAI.69.2.681-686.2001.
7
Development of a preventive vaccine for Ebola virus infection in primates.
Nature. 2000 Nov 30;408(6812):605-9. doi: 10.1038/35046108.
8
Induction of CD8+ T cells using heterologous prime-boost immunisation strategies.
Immunol Rev. 1999 Aug;170:29-38. doi: 10.1111/j.1600-065x.1999.tb01326.x.
9
Designing blood-stage vaccines against Babesia bovis and B. bigemina.
Parasitol Today. 1999 Jul;15(7):275-81. doi: 10.1016/s0169-4758(99)01471-4.
10
Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara.
Nat Med. 1998 Apr;4(4):397-402. doi: 10.1038/nm0498-397.
Zotero 插件